

Special Issue

High-Risk Neuroblastoma and Rhabdoid Tumors: New Clinical Insights and Challenges (Second Edition)

Message from the Guest Editors

Neuroblastoma is the most common extracranial solid tumor in young children and typically presents at an average age of 1 to 2 years. Occasionally, newborns can present with metastatic neuroblastoma, and adolescents or younger adults can also be affected. In newborns, even disseminated neuroblastoma can spontaneously regress without any therapy, whereas metastasized neuroblastoma in toddlers and older patients is highly aggressive and associated with a poor prognosis. These features make neuroblastoma a tumor with one of the highest spontaneous regression rates, on the one hand, and one of the most aggressive tumors, on the other, due to its tendency to recur after initial treatment. The biology behind these features is slowly beginning to be understood, but there are still major challenges, especially in the treatment of high-risk patients. In this second edition, we welcome authors to submit original papers or reviews on current and future new diagnostic and treatment strategies of children with high-risk neuroblastoma. We also invite original research papers regarding new treatment strategies for rhabdoid tumors.

Guest Editors

Prof. Dr. Rupert Handgretinger

1. Senior Professor, Department of Hematology/Oncology, Children's Hospital, University Hospital Tübingen, 72076 Tübingen, Germany
2. George and Jennifer Yeo Endowed Chair in Pediatric Oncology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

Prof. Dr. Johannes Hubertus Schulte

Director, Department of Pediatric Oncology/Hematology, Children's Hospital, University Hospital Tübingen, 72076 Tübingen, Germany

Deadline for manuscript submissions

closed (25 May 2026)



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/237414

Journal of Clinical Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

mdpi.com/journal/

jcm





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
jcm](https://mdpi.com/journal/jcm)



About the Journal

Message from the Editor-in-Chief

Journal of Clinical Medicine (ISSN 2077-0383) is an international, peer-reviewed, open access journal dedicated to advancing clinical and preclinical research. Our Editorial Board and staff are committed to delivering cutting-edge, timely, peer-reviewed articles spanning the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and impactful research articles, as well as reviews that are clinically significant and relevant to the full spectrum of medical disciplines. All full texts are archived in PubMed Central and indexed in SCIE (Web of Science), Scopus, PubMed, and other major databases. We invite you to submit your manuscript for publication, as well as join our community as a reviewer or reader online.

Editors-in-Chief

Prof. Dr. Emmanuel Andr s

Internal Medicine Department, University Hospital Strasbourg, 67000
Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1
(General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).